Medicus Pharma Ltd. (NASDAQ: MDCX)
- Jake Rivers
- Sep 6
- 2 min read
Transforming Oncology & Vaccine Therapeutics
Medicus Pharma Ltd. (NASDAQ: MDCX) is a clinical-stage, multi-strategy holding company dedicated to investing in innovative life sciences and biotechnology firms through FDA-approved clinical trials. The Company specializes in identifying, acquiring, and advancing relatively de-risked clinical-stage assets throughout their development and commercialization phases. To enhance its drug development pipeline, Medicus Pharma is actively pursuing acquisitions and strategic partnerships. Through its subsidiary, SkinJect, Inc., the Company is focused on developing a cutting-edge drug delivery system utilizing novel dissolvable microneedle arrays for the treatment of specific skin cancers. SkinJect represents a minimally invasive approach to treating common forms of non-melanoma skin cancer, including basal cell carcinoma and squamous cell carcinoma.
Vanderbiltreport Alert - This stock is a Sleeping Giant
Investment Highlights
Diversified Clinical Pipeline
- SkinJect / D-MNA Microneedle Patch – Phase
2 trial for basal cell carcinoma underway; FDA engagement progressing.
- Teverelix (via Antev Acquisition) – GnRH antagonist for prostate cancer & acute urinary
retention, addressing a $6B+ market opportunity.
- mRNA + Microneedle Collaboration (HelixNano) –
Thermostable vaccines for infectious diseases. Strong Financial Position
- $9.7M cash on hand (Q2 2025).
- Recently raised $4.2M via Reg A + $7.0M public offering.
- Acquisition structured with milestone-based payments, limiting dilution. Leadership &
Execution
- Proven biotech veterans onboard, including Patrick J. Mahaffy (Clovis Oncology, Pharmion).
- Strategic hires and Deloitte engaged to explore out-licensing opportunities.
Call your Broker now!
Market Opportunity
- Skin Cancer (Basal Cell Carcinoma): >5M new U.S. cases annually, ~$2B addressable market.
- Prostate Cancer & Urology: ~$6B+ combined global opportunity.
- Global Vaccines: Expanding market with delivery & distribution advantages.
Why Invest Now?
✔ Late-stage assets with clear regulatory milestones.
✔ Multiple shots on goal in oncology, urology, and vaccines.
✔ Strengthened balance sheet and capital-efficient acquisitions.
✔ Experienced team with track record of building and scaling biotechs.
Join us in building wealth, one investment at a time
Contact Investor Relations
DISCLAIMER
Snapmediagroup.net and Vanderbiltreport.com are owned and operated by SMG a US-based corporation. We have received compensation of up to $100,000 regarding the profiling of Medicus Pharma Ltd. (Nasdaq: MDCX) starting on Sept 5, 2025. It is important to note that we do not own any shares in MDCX: NASDAQ.
Comments